Treatment
Growth Hormone clinical trials
We’re tracking 53 recruiting studies that include Growth Hormone, each written for real people, not researchers, below.
Recruiting studies
- NCT05144035RecruitingPhase 4
Early growth-hormone treatment for small baby’s brain development
This study tests whether starting a growth hormone treatment early helps a baby’s thinking and learning development. It is for babies who are small for their gestational age and show delays on a developmental screening test.
Wuhan, WuhanAges 6 months–2 years - NCT06382155RecruitingPhase 2
Vosoritide for children with idiopathic short stature
This trial tests a medication called vosoritide to see if it can help children with unexplained short stature grow taller. It's for kids who are very short for their age but have normal growth hormone levels and no other known cause.
California City, CaliforniaAges 3–11 - NCT06927310RecruitingPhase 3
Growth Hormone Injection for Idiopathic Short Stature in Children
This study tests a new growth hormone injection (Inpegsomatropin) to help children with idiopathic short stature (short stature with no known cause) grow taller. It may be an option if your child is very short compared to peers and has not started puberty.
Hefei, AnhuiAges 3–11 - NCT07309562RecruitingPhase 3
Growth hormone trial for short children born small
This study tests an experimental growth hormone (Inpegsomatropin) to help children born small for gestational age who remain short. If your child meets the specific height, age, and puberty criteria, they may qualify.
BeijingAges 2–11 - NCT07323329RecruitingPhase 2/Phase 3
Growth Hormone and DHEA for IVF in Women with Low Ovarian Reserve
This trial tests whether adding growth hormone and DHEA to your IVF medications can help women with low ovarian reserve get more eggs and improve pregnancy chances. It may be an option if you are over 40, have had few eggs before, or have low egg count markers.
Banī Suwayf, Beni Suweif GovernorateAges 18–35 - NCT04798690Recruiting
Long-term growth injections for short children
This trial studies the long-term safety and effectiveness of Growtropin®-II, a growth hormone–type injection, in children who are short due to certain causes. It may help your child’s growth over time, while also closely tracking side effects.
Seoul, Seodaemun-guAges 2 years+ - NCT03812913Recruiting
Brain and learning testing in girls with Turner syndrome
This study uses age-appropriate neuropsychological (thinking and learning) tests in girls to understand how brain functioning differs in Turner syndrome compared with isolated growth hormone deficiency. It may help doctors better assess learning and support needs.
Rennes, Ile Et VilaineAges 7–16 - NCT05470504RecruitingPhase 2
Pegvisomant for severe insulin resistance from rare fat or gene problems
This Phase 2 study tests pegvisomant, a medicine that blocks growth hormone, to see if it can improve severe insulin resistance in people with a specific genetic cause or a rare fat distribution condition. If you fit the rare diagnosis, the study may help clarify whether growth-hormone blocking can improve blood sugar and related health markers.
Bethesda, MarylandAges 18–70 - NCT05775523Recruiting
Safety follow-up study for children using lonapegsomatropin
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
Phoenix, ArizonaAges 1–18 - NCT05820672Recruiting
Study of people using Skytrofa in the United States
This study looks at how well and how safely Skytrofa (lonapegsomatropin) works for real-world patients in the U.S. It mainly gathers information from routine care to help doctors understand expected benefits and side effects.
Phoenix, ArizonaAges Any age - NCT06542809Recruiting
Growth hormone medicine change survey for kids
This survey asks children and teens currently using daily growth hormone shots if they would like to switch to a longer-acting medicine that requires fewer injections. Your answers will help doctors understand patient preferences.
Brussels, Woluwe-saint-lambertAges 1 day–18 years - NCT06571487Recruiting
Growth hormone resistance in beta cells after pregnancy
This study looks at how the body's insulin-making cells (beta cells) might become resistant to growth hormone after a full-term pregnancy. It compares women who had gestational diabetes to those who didn't, to learn more about diabetes risk. You may join if you had a healthy single-baby pregnancy in the last 5 years and never had type 1 or type 2 diabetes.
Columbia, MissouriAges 18–45 - NCT06571500Recruiting
Growth hormone and insulin cells in type 2 diabetes risk
This study looks at how growth hormone affects insulin-making cells in people at risk for type 2 diabetes. It may help explain why some people with a family history of diabetes develop the condition.
Columbia, MissouriAges 18–59 - NCT06587035Recruiting
Study of somatrogon for pediatric growth hormone deficiency in India
This study looks at how well somatrogon works for children 3 years and older with growth hormone deficiency. It may help you understand if this treatment is an option for your child.
Bengaluru, KarnatakaAges 3–17 - NCT07359625Recruiting
Study on ketone drinks and insulin health
This study tests if drinking a ketone supplement can improve how your body responds to insulin, which affects blood sugar control.
Aarhus NAges 55–70 - NCT07412782Recruiting
REMS bone scan study for children with bone conditions
This study uses a new ultrasound technology called REMS to check bone health in children aged 5 to 18 who have conditions that weaken bones. It may help find low bone density without radiation.
Florence, TuscanyAges 5–18 - NCT07568574Enrolling by invitation
Medical Study of Performance-Enhancing Substances in Elite Athletes
This study looks at how medically supervised performance-enhancing substances affect elite athletes' health and quality of life. Participants must be retired from professional sports and willing to undergo careful medical monitoring throughout the trial.
Abu DhabiAges 18 years+ - NCT03338387Enrolling by invitationPhase 2
Test effects of gut hormones in bulimia
This trial studies how growth-related and gut hormones affect ghrelin, a hunger-related hormone, in people with bulimia. It may help researchers understand the body changes behind bulimia and how hormones and appetite signals work.
Ages 18–30 - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06756932RecruitingPhase 1
Bcl-2 inhibitor combo for advanced HR+ breast cancer
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Iowa City, IowaAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+ - NCT05760612RecruitingPhase 3
After breast cancer surgery, test neratinib plus trastuzumab
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
GuangzhouAges 18–70 - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT06263543RecruitingPhase 2
Sequencing antibody-drug conjugates in ER+, HER2-low breast cancer
This trial tests different sequences of antibody-drug conjugates (a type of targeted chemotherapy) for people with ER-positive, HER2-low or ultra-low metastatic breast cancer that has stopped responding to hormone therapy and has progressed on Enhertu. You must have had 1–4 prior chemotherapies for metastatic disease.
Miami, FloridaAges 18 years+
Common questions
- Are there clinical trials studying Growth Hormone?
- Yes. Clin2 currently lists 53 recruiting studies that include Growth Hormone, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Growth Hormone trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Growth Hormone an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Growth Hormone or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.